Shopping Cart
- Remove All
- Your shopping cart is currently empty
R916562 is an orally active, selective Axl/VEGF-R2 inhibitor with IC50 values of 136 nM and 24 nM, respectively, demonstrating anti-angiogenesis and anti-metastasis properties.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | R916562 is an orally active, selective Axl/VEGF-R2 inhibitor with IC50 values of 136 nM and 24 nM, respectively, demonstrating anti-angiogenesis and anti-metastasis properties. |
Targets&IC50 | VEGFR2:24 nM, Axl:136 nM |
In vivo | Treatment with R916562 at dosages of 85 mg/kg or 125 mg/kg (administered orally twice daily for 21 days) leads to statistically significant tumor growth inhibitions of 69% and 83%, respectively. Additionally, R916562 achieves a 73% reduction in fibroblast growth factor-induced neovascularization in the mouse corneal micropocket assay at 100 mg/kg, and a 50% reduction at 50 mg/kg[1]. |
Molecular Weight | 536.09 |
Formula | C26H30ClN9S |
Cas No. | 1037798-41-6 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.